Takeda announced cash tender offer for TiGenix at EUR 1.78/share (~EUR 520M / ~$640M) on January 5, 2018, with the offer launched February 8, 2018. Builds on a 2016 ex-US license for Cx601 (Alofisel), a first-in-class allogeneic stem cell therapy for complex perianal fistulas in Crohn's disease, strengthening Takeda's late-stage GI pipeline with US footprint potential.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
AnnouncedFeb 08, 2018
ClosedJul 19, 2018
Deal value$640M
Deal typeAcquisition/Merger
Therapeutic areaComplex perianal fistulas in Crohn's disease
IndicationsComplex perianal fistulas in Crohn's disease